ARTICLE

Received 27 Feb 2015 | Accepted 20 Aug 2015 | Published 24 Sep 2015

DOI: 10.1038/ncomms9423

OPEN

Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection

Samia Akthar¹, Dhiren F. Patel¹, Rebecca C. Beale¹, Teresa Peiró¹, Xin Xu², Amit Gaggar^{2,3,4}, Patricia L. Jackson², J. Edwin Blalock^{2,4}, Clare M. Lloyd¹ & Robert J. Snelgrove¹

Bioactive matrix fragments (matrikines) have been identified in a myriad of disorders, but their impact on the evolution of airway inflammation has not been demonstrated. We recently described a pathway where the matrikine and neutrophil chemoattractant proline-glycine-proline (PGP) could be degraded by the enzyme leukotriene A₄ hydrolase (LTA₄H). LTA₄H classically functions in the generation of pro-inflammatory leukotriene B₄, thus LTA₄H exhibits opposing pro- and anti-inflammatory activities. The physiological significance of this secondary anti-inflammatory activity remains unknown. Here we show, using readily resolving pulmonary inflammation models, that loss of this secondary activity leads to more pronounced and sustained inflammation and illness owing to PGP accumulation. PGP elicits an exacerbated neutrophilic inflammation and protease imbalance that further degrades the extracellular matrix, generating fragments that perpetuate inflammation. This highlights a critical role for the secondary anti-inflammatory activity of LTA₄H and thus has consequences for the generation of global LTA₄H inhibitors currently being developed.

¹Leukocyte Biology Section, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK. ²Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham and Lung Health Center, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 3529, USA. ³Gregory Fleming James Cystic Fibrosis Center and Program in Protease and Matrix Biology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. ⁴Birmingham V.A. Medical Center, Birmingham, Alabama 35294, USA. Correspondence and requests for materials should be addressed to R.J.S. (email: robert.snelgrove@imperial.ac.uk).

Neutrophils are critical components of the body's immune response, being readily mobilized to the site of infection and destroying invading micro-organisms^{1,2}. Recruitment of neutrophils into the tissue in response to infection is mediated by an array of chemoattractant signals, including lipid molecules such as leukotriene B₄ (LTB₄) and the glutamic acid-leucine-arginine⁺ (ELR⁺) class of chemokines. ELR⁺ chemokines, including interleukin (IL)-8 in humans and KC and MIP-2 in mice, exert their activity by binding to receptors CXCR1/2 (ref. 3). Despite their clear antimicrobial capacity, neutrophils are not indiscriminate killers but their inflammation is tightly regulated and they are able to elegantly and specifically shape many facets of the elicited immune response^{4,5}. However, owing to their potent arsenal, an over-exuberant or persistent neutrophilic inflammation is implicated in the pathologies of chronic diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF)^{6,7}.

A protease-antiprotease imbalance is a hallmark of many chronic lung diseases, with the presence and activity of several matrix metalloproteinases (MMPs) and neutrophil elastase (NE), in particular, correlating with COPD pathology. Such proteases target the extracellular matrix (ECM) for degradation, disrupting tissue architecture and releasing ECM-derived chemoattractant signals, termed 'matrikines', which can perpetuate inflammation⁸. Models of exposure to cigarette smoke show that both breakdown of ECM (by neutrophil or macrophage elastase) and accumulation of neutrophils are required for pathological changes^{9–12}. It is plausible therefore that a protease-/matrikine-driven inflammation may underlie the pathology observed in such chronic diseases.

The tripeptide proline-glycine-proline (PGP) is one such matrikine, being a neutrophil chemoattractant derived from ECM collagen that exerts its activity by mimicking key sequences found in ELR⁺ chemokines and binding to CXCR1/2 (ref. 13). PGP is generated from collagen via the sequential enzymatic activity of MMPs (specifically MMP-8 and -9) and prolylendopeptidase (PE)¹⁴. Significant quantities of PGP are found in patients with chronic lung diseases such as COPD, CF and bronchiolitis obliterans syndrome^{14–18}. Recently, we have identified a novel anti-inflammatory pathway whereby PGP is readily degraded by the extracellular activity of the enzyme leukotriene A₄ hydrolase (LTA₄H)¹⁹. We subsequently demonstrated that this LTA₄H-mediated PGP degradation is perturbed by cigarette smoke, contributing to the accumulation of PGP in COPD^{18,19}.

LTA₄H is classically recognized for its intracellular epoxide hydrolase activity, whereby it generates the pro-inflammatory lipid mediator LTB₄ (refs 20,21). LTB₄ may bind to receptors BLT1 or BLT2; while BLT1 is a high-affinity and specific receptor for LTB₄, BLT2 binds LTB₄ with substantially lower affinity and can also bind to other eicosanoids²². The physiological functions of LTB₄ are attributed to signalling through BLT1. LTB₄ can drive the recruitment and activation of an array of cells including neutrophils and is thus implicated in protection against invading micro-organisms but also in the pathology of an array of diseases^{23–27}. Thus, LTA₄H represents an unusual enzyme with opposing pro- and anti-inflammatory activities that dictate the amplitude and persistence of neutrophilic inflammation²⁸. There has been significant interest from pharmaceutical companies to target LTA₄H therapeutically to alleviate LTB₄-mediated pathologies, but despite the generation of several excellent inhibitors, these drugs have failed to demonstrate clinical efficacy^{29,30}. The lack of success of these compounds could feasibly be due to their failure to distinguish between the opposing roles of LTA₄H and thus inadvertently prevent PGP degradation.

The critical role of LTA₄H in generating LTB₄ and the significance of this lipid mediator in multiple inflammatory settings are undeniable. While it is clear that LTA₄H possesses a secondary anti-inflammatory role in degrading PGP, the relative physiological significance of this activity remains unclear. To address this, we have manipulated the LTA₄H pathways in a murine model of *Haemophilus influenzae* b (Hib). *H. influenzae* is a Gram-negative coccobacillus, of which there are encapsulated and unencapsulated strains^{31,32}. Unencapsulated strains are termed non-typeable (NTHI) and are frequent causes of exacerbations of COPD and asthma. Encapsulated strains are divided into serotypes, of which there are six (a–f), based on their capsular antigen. Serotype B (Hib) is the cause of most invasive *H. influenzae* infections, which include pneumonia, meningitis, septicaemia and epiglottitis³³. However, in most people Hib is found as a commensal of the nasopharynx, with the bacteria becoming invasive in only a small number of cases.

The murine model of Hib infection was chosen to dissect the dual activities of LTA₄H, as it represents a non-complicated infection whereby the pathogen is readily cleared but elicits a robust pulmonary neutrophilia that is rapidly resolved. In this setting, it is feasible to address whether a failure to degrade PGP can lead to an augmented and prolonged neutrophilia to what is a relatively innocuous pulmonary insult. It thus provides an ideal model to probe the relative roles of LTB₄ and PGP in protection and pathology. In this context, LTB₄ was shown to be critical to bacterial phagocytosis and killing on a per-cell basis, but did not control the magnitude of the inflammatory response or illness. Conversely, a failure of LTA₄H-mediated degradation of PGP led to accumulation of the peptide and a marked augmentation in inflammation and illness. This manifested primarily as a PGP-mediated increase in neutrophil numbers in the lung and airways, and a secondary protease imbalance that resulted in generation of elastin-derived matrikines that promoted a secondary macrophage infiltrate. Thus the failure to degrade PGP can have significant deleterious consequences, highlighting the key physiological role of the secondary anti-inflammatory activity of LTA₄H and the prominent pathological role of PGP in inducing a general protease-matrikine imbalance.

Results

Dual-LTA₄H activities are functional during Hib infection.

Infection of 129/S6 mice with Hib elicited a transient, mild weight loss peaking at 24–48 h post infection, which correlated with the size of the inoculating dose of bacteria (Fig. 1a). Coinciding with peak illness was a robust, readily resolving inflammation observed in the airways (Fig. 1b) and lungs (Fig. 1c). Consequently, bacteria were promptly cleared from the airways (Fig. 1d) and lung parenchyma (Fig. 1e) of infected mice. The pulmonary infiltrate was predominantly neutrophilic, with Hib inducing a rapid, dose-dependent, influx of neutrophils peaking at 24 h post infection (Fig. 1f,g). Secondary to this neutrophilic inflammation was a relatively modest infiltration of monocytes/macrophages, natural killer cells and T cells (Supplementary Fig. 1A–E, respectively). Within this system, alveolar macrophages (Supplementary Fig. 1F–H) and neutrophils (Fig. 1h,i) were critical to the clearance of Hib, as their depletion significantly compromised bacterial clearance.

The arrival of neutrophils into the lungs and airways of Hib-infected mice was preceded by the release of ELR⁺ CXC chemokines KC (Fig. 1j) and MIP-2 (Fig. 1k) into the bronchoalveolar lavage fluid (BALF). Furthermore, conventional intracellular epoxide hydrolase activity of LTA₄H was augmented by infection (Fig. 1l) and the neutrophil chemoattractant LTB₄ was released into the BALF (Fig. 1m). This elevation in epoxide

Figure 1 | Dual-LTA₄H activities are functional during Hib infection. 129/S6 mice were infected with Hib and weight loss assessed daily (a). Total cell numbers in the airways (b) and lung tissue (c) of Hib-infected mice were measured. Bacterial burden was assessed by performing serial dilutions of BALF (d) and lung homogenate (e) on Brain Heart Infusion agar. The number of neutrophils recruited to the airways (f) and lung tissue (g) of Hib-infected mice was determined by flow cytometry. Mice infected with 1×10^7 Hib were administered control (2A3) or neutrophil-depleting (1A8) antibody, and neutrophil numbers (h) and c.f.u. (i) were assessed at 24 h post infection. The concentration of KC (j) and MIP-2 (k) in the BALF was determined by ELISA. Intracellular epoxide hydrolase activity of BAL cells (l). LTB₄ levels in BALF of Hib-infected mice (m). Mice infected with 1×10^7 Hib were administered 2A3 or 1A8 antibody and intracellular epoxide hydrolase activity of BAL cells determined at 24 h post infection (n). Amounts of total MMP-9 (o) in BALF were assessed by ELISA and MMP-9 gelatinolytic activity (p) was assessed by gelatin zymography (representative image depicted: lane 1 = naive; 2 = 1×10^6 6 h; 3 = 1×10^7 6 h; 4 = 1×10^6 24 h; 5 = 1×10^7 24 h; 6 = 1×10^6 day 3; 7 = 1×10^7 day 3; 8 = 1×10^6 day 7; 9 = 1×10^7 day 7). (q) PE activity in BALF at different times after Hib infection. Mice infected with 1×10^7 Hib were administered 2A3 or 1A8 antibody, and total MMP-9 levels (r) and PE activity (s) in the BALF were determined at 24 h post infection. Total LTA₄H levels in BALF were assessed by ELISA at different times post infection (t). BALF, from different time points post Hib infection, was incubated with PGP and degradation was assessed after 2 h by mass spectrometry (u) or release of free proline (v). Mice infected with 1×10^7 Hib were administered 2A3 or 1A8 antibody and PGP degradation by BALF at 24 h was assessed by mass spectrometry (w) or release of free proline (x). Data (mean $\pm$ s.e.m.) are representative of at least two experiments with 5–6 mice per group. * $P < 0.05$; ** $P < 0.01$ using the Mann-Whitney test.

hydrolase activity of LTA₄H was seemingly attributable to the substantial neutrophilic infiltrate, with the activity markedly reduced following neutrophil depletion (Fig. 1n). Key PGP-generating enzymes MMP-9 (Fig. 1o,p) and PE (Fig. 1q) were

induced by Hib infection, but PGP was undetectable at any time point. Neutrophils are a prominent source of these PGP-generating enzymes enabling a feed-forward vicious circle of neutrophilic inflammation^{14,19,34–36}. Accordingly, neutrophil

depletion in Hib-infected mice resulted in a significant reduction in BALF MMP-9 levels (Fig. 1r) and PE activity (Fig. 1s). The failure to detect PGP, despite the presence of MMP-9/PE, could be attributable to extracellular release of LTA₄H (Fig. 1t) and its capacity to degrade PGP (Fig. 1u,v). As previously postulated¹⁹, neutrophils are likely a source of extracellular LTA₄H, as their depletion resulted in reduced capacity of BALF to degrade PGP (Fig. 1w,x). Thus both the pro-inflammatory LTB₄-generating and the anti-inflammatory PGP-degrading activities of LTA₄H are operational within this acute pulmonary neutrophilia model. The nature of this elicited response to Hib observed in 129/S6 mice was comparable in Balb/c and C57BL/6 mice (Supplementary Fig. 2).

Loss of LTB₄ signalling compromises Hib clearance. Physiological functions attributed to LTB₄ are relayed through receptor BLT1. To infer the role of LTB₄ in our Hib model, wild-type (WT) and *blt1*^{-/-} mice were infected with 1×10^7 colony-forming unit (c.f.u.) of Hib. WT and *blt1*^{-/-} mice

displayed comparable weight loss (Fig. 2a) and inflammation into the airways (Fig. 2b) and lung parenchyma (Fig. 2c) in response to Hib. Specifically, neutrophilic inflammation into the airways (Fig. 2d) and lung tissue (Fig. 2e) was indistinguishable between Hib-infected WT and *blt1*^{-/-} mice. Despite comparable cellular inflammation, clearance of Hib was compromised in *blt1*^{-/-} mice at 6 (Fig. 2f) and 24 h (Fig. 2g) post infection. A plethora of studies have highlighted the capacity of LTB₄ to augment the phagocytic and antimicrobial potential of macrophages and neutrophils on a per-cell basis^{26,37–50}. Alveolar macrophages (Fig. 2h) and neutrophils (Fig. 2i) from *blt1*^{-/-} mice exhibited a significant reduction in their capacity to phagocytose pHrodo-labelled Hib relative to WT controls. Furthermore, *blt1*^{-/-} alveolar macrophages (Fig. 2j) and neutrophils (Fig. 2k) exhibited reduced bacterial killing of Hib on a per-cell basis relative to WT counterparts.

The comparable cellular inflammation but compromised bacterial clearance observed at 24 h post infection in Hib-infected *blt1*^{-/-} mice relative to WT controls was recapitulated through administration of a BLT1-specific antagonist U-75302

Figure 2 | An absence of LTB₄ signalling does not alter pulmonary inflammation but compromises bacterial clearance. *Blt1*^{-/-} mice and WT controls were infected intranasally with 1×10^7 Hib and weight loss was assessed daily and expressed as a percentage of the original body mass (**a**). Total cell numbers in the airways (**b**) and lung tissue (**c**) of Hib-infected mice were enumerated. The number of neutrophils recruited into the airways (**d**) and lung tissue (**e**) of Hib-infected mice was determined by flow cytometry. Bacterial burden was assessed by performing serial dilutions of BALF and lung homogenate, at 6 h (**f**) and 24 h (**g**), on Brain Heart Infusion (BHI) agar plates. Phagocytosis of pHrodo-conjugated Hib by alveolar macrophages (**h**) and neutrophils (**i**) was assessed by flow cytometry. The capacity of WT and *blt1*^{-/-} alveolar macrophages (**j**) and neutrophils (**k**) to kill Hib was assessed. Hib-infected mice were administered vehicle (PBS), BLT1 antagonist (U-75302) or BLT2 antagonist (LY2552833), and lung neutrophil numbers (**l**) and c.f.u. (**m**) were assessed at 24 h post infection. Data (mean $\pm$ s.e.m.) are representative of at least two experiments with 5–6 mice per group. **P* < 0.05; ***P* < 0.01 using the Mann-Whitney test.

to Hib-infected WT mice (Fig. 2l,m). Administration of a preferential BLT2 antagonist LY2552833 to Hib-infected WT mice had no effect on cellular inflammation or bacterial clearance (Fig. 2l,m), suggesting that BLT2 is not important in regulating these parameters within this model.

The enzyme 5-lipoxygenase (5-LO) generates leukotriene A₄ (LTA₄), which is subsequently hydrolysed by LTA₄H into LTB₄ (Supplementary Fig. 3A). To further verify the role of LTB₄ in the outcome of Hib infection, we administered the 5-LO inhibitor zileuton to infected animals. While zileuton will inhibit LTB₄ formation, there is the caveat that it could also disrupt production of cysteinyl leukotrienes (LTC₄, D₄, E₄) and lipoxins since they share a common LTA₄ intermediate (Supplementary Fig. 3A). Zileuton-administered Hib-infected mice showed comparable cellular inflammation into the airways and lungs at 24 h (Supplementary Fig. 3B,C) relative to control-treated animals. Furthermore, zileuton administration did not alter neutrophil numbers (Supplementary Fig. 3D,E) but did compromise bacterial clearance (Supplementary Fig. 3F,G).

Hib-infected *lta4h* −/− mice display augmented inflammation.

Having inferred the role of LTB₄ in Hib infection, it was now of interest to determine the phenotype of Hib-infected *lta4h* −/− mice that lack not only the classical pro-inflammatory LTB₄-generating activity but also the anti-inflammatory PGP-degrading activity. WT and *lta4h* −/− mice were infected with 1×10^7 c.f.u. of Hib and ensuing illness and inflammation assessed. Hib-infected *lta4h* −/− mice exhibited a more pronounced weight loss that was slower to resolve relative to WT controls (Fig. 3a). In keeping with a more pronounced illness in *lta4h* −/− mice, they also displayed augmented pulmonary oedema (Fig. 3b) and cellular damage (Fig. 3c). The more pronounced illness observed in Hib-infected *lta4h* −/− mice relative to WT controls was not attributable to compromised bacterial clearance, as c.f.u. were comparable in BALF (Fig. 3d) and lung parenchyma (Fig. 3e). Instead, Hib-infected *lta4h* −/− mice showed a marked increase in cellular infiltrate into their airways (Fig. 3f) and lung tissue (Fig. 3g) relative to the WT animals, which was largely attributable to a substantial increase in neutrophils (Fig. 3h,i). Secondary to the augmented neutrophilia seen in *lta4h* −/− mice was an elevated infiltration of monocytes/macrophages into the airways (Fig. 3j) and lung tissue (Fig. 3k) relative to WT controls.

PGP drives an exacerbated neutrophilic inflammation to Hib.

The augmented neutrophilic inflammation observed in Hib-infected *lta4h* −/− mice, despite the absence of LTB₄ (Fig. 4a), was not attributable to an elevation in KC and MIP-2 since levels in BALF (Fig. 4b,c) were comparable between WT and *lta4h* −/− mice. Other neutrophil chemoattractants C5a, lungkine/CXCL15 and ENA-78/CXCL5 were also comparable between WT and *lta4h* −/− mice (Supplementary Fig. 4A–C). Levels of pro-inflammatory cytokines tumour-necrosis factor (TNF)-α (Fig. 4d) and IL-6 (Fig. 4e), which can regulate neutrophil recruitment, were elevated at 24 h in Hib-infected *lta4h* −/− mice, but seemed insufficient alone to drive the observed phenotype. However, while no PGP was detectable in the BALF of Hib-infected WT mice, significant quantities were present in *lta4h* −/− animals (Fig. 4f). Accordingly, the capacity of BALF to degrade PGP was absent in Hib-infected *lta4h* −/− mice (Fig. 4g,h). PGP administration to Hib-infected WT mice augmented airway neutrophilia (Fig. 4i) and promoted bacterial clearance (Fig. 4j), supporting the notion that the phenotype of the *lta4h* −/− animals could be attributable to PGP accumulation.

To verify that the exacerbated illness and neutrophilic inflammation observed in *lta4h* −/− mice was due to PGP accumulation, we utilized a complementary peptide that specifically antagonizes PGP, namely arginine–threonine–arginine (RTR)^{36,51}. Hib-infected WT and *lta4h* −/− mice were administered RTR, and inflammation and bacterial burden were assessed at 24 h post infection. While WT mice again displayed no PGP in their airways, control and RTR-treated *lta4h* −/− mice exhibited substantial quantities, highlighting that RTR does not reduce levels of PGP but rather binds and antagonizes it (Fig. 4k)⁵². Administration of RTR to Hib-infected *lta4h* −/− mice completely negated the augmented cellular infiltrate seen in the airways (Fig. 4l) and lungs (Fig. 4m) of these mice above that observed in the WT controls. Furthermore, administration of RTR to *lta4h* −/− mice compromised bacterial clearance (Fig. 4n)—presumably due to the loss of LTB₄ and now the compensatory PGP that had previously conferred some augmented protection. In keeping with the role of PGP, the reduction in pulmonary inflammation observed in Hib-infected *lta4h* −/− mice administered RTR was due to a diminished neutrophilic infiltrate (Fig. 4o,p). The previously observed heightened TNF-α and IL-6 release in Hib-infected *lta4h* −/− mice (Fig. 4d,e) was normalized to WT levels following RTR treatment (Fig. 4q,r), suggestive that it is secondary to PGP. As a point of note, it has been suggested that loss of LTA₄H function can lead to an accumulation of LTA₄ and a subsequent lipoxin shunt, whereby levels of anti-inflammatory lipoxins are increased⁵³. If this were the case in Hib-infected *lta4h* −/− mice, then one may envisage a reduced inflammation in response to the bacteria rather than the substantial PGP-driven increase observed. Furthermore, within our model system no lipoxins were detectable at any time point.

Greater monocyte influx in Hib-infected *lta4h* −/− mice. PGP is a neutrophil chemoattractant and thus while it is rational that a greater neutrophil infiltrate is observed in *lta4h* −/− mice infected with Hib, it cannot explain the augmented ensuing infiltration of monocytes (Fig. 3j,k). Furthermore, there were comparable levels of classical monocyte-attracting chemokines preceding this monocytic infiltrate in *lta4h* −/− mice and littermate controls (Supplementary Fig. 4D–G). While collagen-derived PGP is not chemotactic for monocytes, elastin-derived matrikines are^{11,54,55}. It was postulated that PGP accumulation in *lta4h* −/− mice may drive augmented neutrophilic inflammation with ensuing augmented elastase activity, elastin fragment generation and monocyte infiltration—in essence a protease/matrikine-driven inflammatory exacerbation.

In keeping with elevated neutrophilic inflammation in Hib-infected *lta4h* −/− mice, there was a significant increase in BALF levels of neutrophil-rich proteases MMP-9 (Fig. 5a) and NE (Fig. 5b). Furthermore, there was an augmentation in MMP-9 messenger RNA (mRNA) reflective of the substantial influx of neutrophils richly expressing this protease (Fig. 5c). Stimulation of bone marrow neutrophils with PGP elicited the release of MMP-9 and NE (Fig. 5d), demonstrating that the peptide was not only capable of recruiting neutrophils but also driving the secretion of their products. Intriguingly, Hib-infected *lta4h* −/− mice also displayed elevated macrophage elastase, MMP-12, levels in BALF (Fig. 5e). MMP-12 is predominantly expressed by alveolar macrophages and not neutrophils. There was no difference in MMP-12 mRNA levels between *lta4h* −/− mice and littermate controls (Fig. 5f), suggestive that increased levels in the BALF of knockout animals was not due to increased expression but rather release from alveolar macrophages.

Figure 3 | Hib-infected *Lta4h*^{-/-} mice display augmented illness and pulmonary inflammation. *Lta4h*^{-/-} mice and littermate controls were infected intranasally with 1×10^7 Hib, and weight loss was assessed daily and expressed as a percentage of the original body mass (**a**). Levels of albumin (**b**) and lactate dehydrogenase (LDH; **c**) in the BALF were assessed by ELISA and an enzymatic assay, respectively. Bacterial burden was assessed by performing serial dilutions of BALF (**d**) and lung homogenate (**e**) on Brain Heart Infusion (BHI) agar plates. Total cell numbers in the airways (**f**) and lung tissue (**g**) of Hib-infected mice was enumerated. The number of neutrophils recruited into the airways (**h**) and lung tissue (**i**) of Hib-infected mice was determined by flow cytometry. The number of infiltrating monocytes/macrophages recruited into the airways (**j**) and lung tissue (**k**) of Hib-infected mice was determined by flow cytometry. Data (mean $\pm$ s.e.m.) are combined from two separate experiments with 4–5 mice per group and are representative of 3–4 experiments. * $P < 0.05$; ** $P < 0.01$ using the Mann-Whitney test.

Figure 4 | Failure to degrade PGP drives an exacerbated neutrophilic inflammation in response to Hib infection. *Lta4h*^{−/−} mice and littermate controls were infected intranasally with 1×10^7 Hib and the concentration of LTB₄ (a), KC (b), MIP-2 (c), TNF-α (d) and IL-6 (e) in the BALF was determined. The concentration of PGP in BALF was determined by ESI-LC/MS/MS (f). BALF from different time points post Hib infection was incubated with PGP and degradation was assessed after 2 h by mass spectrometry (g) or release of free proline (h). Mice were infected intranasally with 1×10^7 Hib and 2 h later treated intranasally with AcPGP or control peptide, AcPPG, and at 24 h post infection the number of neutrophils recruited into airways was determined by flow cytometry (i) and the bacterial burden in the BALF was assessed by performing serial dilutions on Brain Heart Infusion (BHI) agar plates (j). *Lta4h*^{−/−} mice and littermate controls infected intranasally with 1×10^7 Hib were administered vehicle or RTR peptide, and the concentration of PGP in BALF was determined by ESI-LC/MS/MS (k). Total cell numbers in the airways (l) and lung tissue (m) enumerated at 24 h post infection. Bacterial burden at this time point was assessed by performing serial dilutions of lung homogenate (n) on BHI agar plates. The number of neutrophils recruited into the airways (o) and lung tissue (p) of Hib-infected mice was determined by flow cytometry. The concentration of TNF-α (q) and IL-6 (r) in the BALF was determined by ELISA. Data (mean ± s.e.m.) are combined from two separate experiments with 4–5 mice per group and are representative of 3–4 experiments (a–h) or are representative of at least two experiments with 5–6 mice per group (i–r). **P* < 0.05; ***P* < 0.01 using the Mann-Whitney test.

In keeping with a blunted PGP-driven neutrophilic inflammation in RTR-treated *lta4h* $-/-$ mice, there was a concomitant reduction in BALF MMP-9 (Fig. 5g) and NE levels were trending down ($P=0.1$; Fig. 5h). Furthermore, BALF levels of MMP-12 (Fig. 5i) were reduced, confirming that augmented levels in *lta4h* $-/-$ animals were secondary to PGP accumulation. NE and MMP-12 can target elastin to generate fragments that are chemotactic for monocytes and could underlie their augmented numbers in Hib-infected *lta4h* $-/-$ mice. To verify this, Hib-infected WT and *lta4h* $-/-$ mice were treated with BA4 antibody (demonstrated to neutralize chemotactic elastin fragments), and cellular infiltrate assessed at day 4 post infection. BA4 administration to Hib-infected *lta4h* $-/-$ mice blunted the elevated cellular infiltrate observed in airways (Fig. 5j) and lungs (Fig. 5k) of these animals and was largely attributable to a reduction in numbers of monocytes/macrophages (Fig. 5l,m).

***S. pneumoniae* infection of *lta4h* $-/-$ mice.** To demonstrate that the exacerbated inflammation seen in Hib-infected *lta4h* $-/-$ mice is not specific to a single model system, we investigated the dual roles of the enzyme following pulmonary infection with the Gram-positive bacteria *Streptococcus pneumoniae*. Infection of 129/S6 mice with *S. pneumoniae* elicited an early weight loss that correlated with size of the inoculating dose of bacteria (Supplementary Fig. 5A). However, unlike with Hib infection, bacterial burden is not efficiently eradicated from the airways or lung tissue (Supplementary Fig. 5B,C). Coinciding with the early weight loss was a robust inflammation in the airways (Supplementary Fig. 5D) and lung tissue (Supplementary Fig. 5E) that was again predominantly neutrophilic (Supplementary Fig. 5F,G). Key PGP-generating enzymes MMP-9 (Supplementary Fig. 5H) and PE (Supplementary Fig. 5I) were readily induced by *S. pneumoniae* infection, but PGP was undetectable at any time point by mass spectrometry. The failure to detect PGP, despite the presence of MMP-9/PE, was again attributable to extracellular release of LTA₄H and its capacity to degrade PGP (Supplementary Fig. 5J).

WT and *lta4h* $-/-$ mice were infected with either 1×10^5 or 1×10^6 c.f.u. of *S. pneumoniae*, and inflammation was assessed 24 h later. *lta4h* $-/-$ mice displayed a significant increase in cellular infiltrate into their airways (Supplementary Fig. 5K) with both doses of bacteria relative to littermate controls, which was largely attributable to a substantial increase in neutrophils (Supplementary Fig. 5L). The augmented neutrophilic infiltrate in *S. pneumoniae*-infected *lta4h* $-/-$ mice relative to controls was not attributable to compromised bacterial clearance (Supplementary Fig. 5M) but rather to an accumulation of PGP (Supplementary Fig. 5N).

Discussion

LTA₄H is the rate-limiting enzyme in LTB₄ biosynthesis, a potent pro-inflammatory mediator implicated in host defence but also

an array of pathological conditions. However, we have recently identified a novel anti-inflammatory role for LTA₄H in degrading the neutrophil chemoattractant PGP¹⁹. The physiological significance of this secondary PGP-degrading activity of LTA₄H has not been addressed, and it is unknown whether a failure to degrade PGP can lead to adverse pathological sequelae, despite the absence of LTB₄. To investigate the dual roles of LTA₄H, we have primarily utilized an acute lung injury model of Hib infection—a model chosen since it evokes a robust pulmonary neutrophilia, but both inflammation and infection are readily resolved without complication. In this setting, it is feasible to assess the significance and risks of failing to degrade PGP and infer the importance of both LTA₄H activities in protection and pathology.

Hib infection of WT mice resulted in an acute pulmonary neutrophilia that, together with resident alveolar macrophages, was important for the efficient clearance of bacteria. Concomitant with this early inflammation was induction of the classical intracellular epoxide hydrolase activity of LTA₄H and release of LTB₄, with neutrophils themselves seemingly the prominent source of the LTB₄. Also concurrent with the pulmonary neutrophilic inflammation was an increase in levels of key PGP-generating enzymes MMP-9 and PE. Neutrophils are a prominent source of MMP-9 and PE and are thus capable of generating PGP and promoting their own recruitment and eliciting a vicious cycle of pathology if left unchecked^{14,19,34–36}. However, despite the robust induction of MMP-9 and PE in response to Hib, no PGP was detectable at any time post infection. This was attributable to the extracellular release of LTA₄H and its potent anti-inflammatory PGP-degrading capacity; thus both LTA₄H activities are operational in our model system. We also report a failure to detect PGP, despite the presence of PGP-generating enzymes, in models of *S. pneumoniae* and influenza infection¹⁹. We would now argue that PGP degradation by LTA₄H is the norm in settings of acute neutrophilia and instrumental in the efficient resolution of inflammation.

LTA₄H is classically a cytosolic enzyme, but to perform its PGP-degrading activity it must be released to an extracellular environment. LTA₄H is reported to exhibit wide tissue and cellular distribution⁵⁶, which has been difficult to rationalize since leukocytes are the only cells to express both LTA₄H and 5-LO required for leukotriene biosynthesis. It is feasible that the capacity of LTA₄H to degrade PGP may account for the disproportionate distribution of LTA₄H and 5-LO. We have previously demonstrated epithelial cells and neutrophils to be prominent sources of extracellular LTA₄H¹⁹. Accordingly, we report a reduction in extracellular LTA₄H in neutrophil-depleted Hib-infected mice. Thus neutrophils are capable of both initiating and resolving their own inflammation through the action of LTA₄H, in disparate cellular locations.

Loss of LTB₄ signalling through the use of *blt1* $-/-$ mice or BLT1 antagonists, or administration of 5-LO inhibitor zileuton, did not alter pulmonary inflammation or illness in

Figure 5 | Augmented macrophage inflammation in Hib-infected *lta4h* $-/-$ mice secondary to PGP accumulation and protease discord. *lta4h* $-/-$ mice and littermate controls were infected intranasally with 1×10^7 Hib and levels of total MMP-9 (a) and NE (b) were assessed by ELISA in the BALF. Levels of MMP-9 mRNA were assessed in lung tissue by real-time PCR (c). Bone marrow neutrophils were incubated with media alone, IL-8 or AcPGP, and levels of MMP-9 and NE were assessed in the supernatant after 15 min (d). Levels of MMP-12 protein in the BALF were assessed by ELISA (e) and MMP-12 mRNA levels in lung tissue assessed by real-time PCR (f). *lta4h* $-/-$ mice and littermate controls infected intranasally with 1×10^7 Hib were administered vehicle or RTR peptide, and the concentration of MMP-9 (g), NE (h) and MMP-12 (i) in the BALF was determined by ELISA at 24 h post infection. To determine the role of elastin-derived chemotactic fragments in driving cellular recruitment, *lta4h* $-/-$ mice and littermate controls infected intranasally with 1×10^7 Hib were administered control or BA4 (anti-elastin) antibody, and total cell numbers in the airways (j) and lung tissue (k) enumerated at 4 days post infection. In the same experiment, the numbers of infiltrating monocytes/macrophages in the airways (l) and lung tissue (m) was determined by flow cytometry at 4 days post infection. Data (mean $\pm$ s.e.m.) are combined from two separate experiments with 4–5 mice per group and are representative of 3–4 experiments (a,b,e) or are representative of at least two experiments with 5–6 mice per group (g–m). Data (mean $\pm$ s.d.) are representative of three experiments with at least triplicates (d). * $P < 0.05$; ** $P < 0.01$ using the Mann–Whitney test.

response to Hib infection, but significantly compromised bacterial clearance. The reduced capacity to control Hib infection in *blt1*^{-/-} mice was attributable to reduced phagocytosis and killing of the bacteria on a per-cell basis by alveolar macrophages and neutrophils. A clear role for LTB₄

in augmenting phagocytosis and microbicidal activity of macrophages and neutrophils is well established^{26,37–50}, with the plethora of studies pertaining to Gram-negative bacteria, *Klebsiella pneumoniae*, particularly pertinent to our studies^{26,37,39,44,45}.

Given the potent pro-inflammatory capacity of LTB₄, it seems counterintuitive that there is not a reduced cellular infiltrate in *blt1* $-/-$ mice or mice administered 5-LO inhibitor zileuton. However, it is interesting to note that reduced neutrophil recruitment to sites of inflammation in 5-LO $-/-$ mice has been observed in some, but certainly not all, experimental models examined^{27,57}. Indeed, a compromised pathogen clearance yet comparable cellular inflammation has been reported previously in mice with a disrupted LTB₄ pathway^{26,42}. Thus it may be that while LTB₄ serves an important function in Hib killing on a per-cell basis, it is not critical for directing cellular inflammation within this model, potentially owing to redundancy with other neutrophil chemoattractants. Alternatively, it is feasible that an absence of LTB₄ signalling reduces cellular inflammation and bacterial clearance, and this augmented TLR burden subsequently yields a greater release of conventional neutrophil chemokines that promote further neutrophil recruitment—thus masking the original deficit.

Lta4h $-/-$ mice administered Hib displayed greater illness, which was attributable to an augmented cellular infiltrate and ensuing immunopathological sequelae. Most notable within this phenotype was the striking increase in neutrophilic inflammation of Hib-infected lta4h $-/-$ mice, despite the loss of LTB₄, and comparable levels of other classical neutrophil chemoattractants. This augmented neutrophilia was attributable to PGP accumulation in lta4h $-/-$ mice, as neutralization of PGP completely ablated neutrophil infiltrate to WT levels. Levels of TNF- α and IL-6, which could regulate neutrophilic inflammation and illness, were also elevated in lta4h $-/-$ mice, but were secondary to PGP accumulation. Thus we show that a failure to degrade PGP has serious implications in the control of neutrophilic inflammation, and that the anti-inflammatory activity of LTA₄H has a clear physiological significance over and above that of its pro-inflammatory action in this setting.

It is perhaps surprising that, despite the clear role of LTB₄ in protection against Hib infection, lta4h $-/-$ mice (which lack LTB₄) displayed a comparable bacterial burden to their littermate controls. However, while lta4h $-/-$ mice lack LTB₄, they possess an increase in PGP and ensuing neutrophilic inflammation that seemingly compensates *in vivo*. Neutrophils are critical effector cells within our Hib model and given the capacity of PGP to drive neutrophil recruitment and effector function, it is not surprising that PGP can prove protective against bacterial challenge, as highlighted by a previous study⁵⁸. Indeed, we demonstrate that PGP administration to Hib-infected WT mice enhances neutrophilic recruitment and bacterial clearance. Furthermore, we clearly demonstrate that PGP is compensating for the loss of LTB₄ and conferring protection against Hib challenge in lta4h $-/-$ mice, as neutralization of the PGP with RTR restored the compromised bacterial clearance.

PGP can drive MMP-9 release from neutrophils and promote a feed-forward system that generates more PGP and further neutrophil recruitment⁵⁹. Accordingly, we demonstrate that PGP can drive MMP-9 release from neutrophils and observe significantly greater MMP-9 levels in Hib-infected lta4h $-/-$ mice—a phenotype that is lost if PGP is neutralized. In addition to MMP-9, we demonstrated Hib-infected lta4h $-/-$ to exhibit a broader protease imbalance with an elevation in NE and MMP-12. The augmented NE is rational, given the elevated neutrophil numbers in lta4h $-/-$ mice and the potential of PGP to drive NE from neutrophils. More surprising was the PGP-dependent increase in MMP-12 in Hib-infected lta4h $-/-$ mice. Neutrophils do not produce MMP-12, and it is likely that alveolar macrophages represent the primary source in our Hib model. PGP is unable to directly elicit the release of MMP-12 from alveolar macrophages and one would predict that release results

from a neutrophil-alveolar macrophage cross-talk. Secondary to the elevated neutrophilia and protease imbalance was an augmented monocytic/macrophage infiltrate in the lta4h $-/-$ mice that was seemingly dependent on elastin-derived matrikines in these mice. While mature, cross-linked elastic fibres are not chemotactic for monocytes, cryptic sequences may be released upon proteolysis by elastolytic enzymes, such as MMP-12 or NE. Such sequences are hydrophobic penta- and hexapeptide repeats such as VGVAPG, which has been demonstrated to be chemotactic for monocytes with optimal activity at ~ 10 nM (refs 60–62). Furthermore, many chemotactic elastin fragments generated *in vivo* are also much larger, and thus the combined chemotactic potential of elastin-derived products towards monocytes could be substantial¹¹. Therefore, the absence of LTA₄H in response to a fairly innocuous challenge gives rise to an accumulation of PGP and neutrophils and a secondary accumulation of elastin-derived matrikines and macrophage numbers (Supplementary Fig. 6)—thus two distinct protease-matrikine systems are inherently linked and the implications of a failure to degrade PGP are significant.

Loss of LTA₄H function clearly resulted in an exacerbated PGP-driven pulmonary inflammation and illness in response to Hib infection. However, the importance of the LTA₄H PGP-degrading activity, even over and above the well-heralded LTB₄-generating activity, is not unique to Hib infection, as we also report a comparable phenotype following challenge with *S. pneumoniae*. Previous interpretation of the role of LTA₄H in neutrophilic inflammation had not considered the unrecognized PGP-degrading secondary activity of LTA₄H and will indeed be complicated by the opposing roles of this bifunctional enzyme. While both 5-LO and LTA₄H knockout mice exhibit reduced inflammation in models of ear inflammation and peritonitis relative to WT mice, the reduction is more pronounced in 5-LO knockouts⁶³. It is feasible that deletion of LTA₄H, while preventing LTB₄ production, may promote PGP levels giving rise to the intermediary phenotype. Furthermore, in an elastase model of emphysema, lta4h $-/-$ animals exhibited a blunted early neutrophilic response that gave way to elevated numbers at later time points—potentially pointing to disparate temporal roles for the two activities of LTA₄H⁶⁴. The significance of LTA₄H and its dual opposing activities in different instances will be complicated by the availability of enzymes that generate LTA₄ and PGP, the relative intra vs extracellular levels of LTA₄H and many other confounding factors. It is feasible therefore that the relative importance of each of LTA₄H's pathways will be disease and even patient specific.

While we demonstrate the result of PGP accumulation in a system where it is normally degraded, it is worth considering the implications of these studies in the context of the chronic diseases where PGP is not efficiently degraded. PGP is elevated in lung diseases such as COPD and CF, often inversely correlating with disease severity^{14–18}. The development of COPD is associated with an accumulation of neutrophils and macrophages and a protease imbalance (specifically MMPs and NE) leading to ECM attack^{10–12}, and there is accumulating evidence that a protease-matrikine-mediated pathology is instrumental in the development of diseases⁵⁴. We have previously demonstrated that cigarette smoke, a key risk factor in the development of COPD, can specifically inhibit the aminopeptidase activity of LTA₄H^{18,19,65}. In light of our current findings, it is likely that the failure of LTA₄H to efficiently degrade PGP is an instrumental and potentially early step in this protease imbalance and augmented neutrophil and macrophage infiltrate. It is also noteworthy that *H. influenzae* and *S. pneumoniae* are common exacerbators of COPD, and that PGP and neutrophils/proteases have been demonstrated to spike with

exacerbations^{17,66,67}. One can thus envisage a scenario whereby such a bacterial challenge leads to further PGP generation in a setting, whereby the peptide cannot be degraded. Targeting the PGP pathway may therefore offer therapeutic potential in chronic neutrophilic lung diseases characterized by PGP accumulation, and in infectious exacerbations of these diseases^{28,68–70}.

It is important to question the significance of these findings in the context of therapeutic strategies that seek to inhibit LTA₄H to reduce LTB₄-mediated pathologies²⁹. There has been a significant pharmaceutical effort to generate LTA₄H inhibitors, but despite the development of drugs that show excellent pharmacokinetic profiles, none of these compounds have shown efficacy in clinical trials. These inhibitors seem unlikely to distinguish between the opposing activities of LTA₄H and may therefore inadvertently prevent PGP degradation with adverse effects.

In conclusion, we show for the first time the consequences of a failure to degrade PGP, highlighting a critical role for the secondary anti-inflammatory activity of LTA₄H. In response to a relatively innocuous pulmonary challenge, accumulation of PGP leads to an augmented neutrophilic inflammation and ensuing illness, as well as a general protease imbalance that targets the ECM and further perpetuates inflammation. These studies have significant implications for our basic understanding of LTA₄H biology, the cross-talk between protease–matrikine networks, the role of PGP in the pathology and development of chronic lung diseases and the design and application of LTA₄H inhibitors by pharmaceutical companies.

Methods

Haemophilus influenzae b. Hib Eagan strain was a kind gift from Professor T. Hussell (Institute of Inflammation and Repair, The University of Manchester, UK). Bacteria were cultured at 37 °C in 5% CO₂ in Brain Heart Infusion (BHI) broth (OXOID, Hampshire, UK) supplemented with 10 µg ml^{−1} of both Hemin (Roche, West Sussex, UK) and nictinamide adenine dinucleotide (Sigma-Aldrich, Dorset, UK) or on BHI agar (OXOID) supplemented with 4% Levinthals. Levinthals was made by adding 50% horse blood (TCS Biosciences, Buckingham, UK) to BHI broth and heating to 70 °C for 45 min. On cooling to 50 °C, 0.7 mg ml^{−1} nictinamide adenine dinucleotide was added and the supernatant was stored at −80 °C. Bacteria were cultured to an optical density (OD)₆₀₀ of 0.3 (~1 × 10⁹ c.f.u. ml^{−1}) and stored at −80 °C in 10% glycerol as single-use aliquots.

S. pneumoniae. *S. pneumoniae* (serotype 2) strain D39 (NCTC 7466, National Collection of Type Cultures, London, UK), a kind gift from Professor T. Hussell (Institute of Inflammation and Repair, The University of Manchester) was cultured at 37 °C in 5% CO₂ on blood agar plates or in Todd-Hewitt broth (OXOID) supplemented with 0.5% yeast extract (OXOID) (THY broth) to an OD₆₀₀ of 0.4 (~1 × 10⁸ c.f.u. ml^{−1}) and stored at −80 °C in 10% glycerol as single-use aliquots.

Mice. Six- to eight-week-old female BALB/c and C57BL/6 mice were purchased from Harlan Olac Ltd (Oxon, UK). *Bltl*^{−/−}, on a C57BL/6 background, were purchased from Jackson Labs (Bar Harbor, ME), and *Lta4h*^{−/−} mice and littermate controls were on a 129/S6 background and a gift from Dr Y.M. Shim (University of Virginia, Charlottesville, VA). All WT 129/S6 mice referred to within the manuscript are littermate controls of *lta4h*^{−/−} mice. All mice were kept in specified pathogen-free conditions and provided autoclaved food, water and bedding. This study was carried out in accordance with the recommendations in the Guide for the Use of Laboratory Animals of Imperial College London. All animal procedures and care conformed strictly to the UK Home Office Guidelines under the Animals (Scientific Procedures) Act 1986, and the protocols were approved by the Home Office of Great Britain.

Lta4h^{−/−} and *Bltl*^{−/−} mice were genotyped by PCR on genomic DNA extracted using the Extract-N-Amp Tissue PCR Kit (Sigma-Aldrich). The WT expression of LTA₄H was detected by primers oIMR1720 (5′-CGAATCCATGCTTAAATTCG-3′) and oIMR1721 (5′-GCGTTACGAACGTGAGACAA-3′) to yield a product size of 128 bp, and *Lta4h*^{−/−} LTA₄H was detected by primers oIMR6916 (5′-CTTGGGTGGAGAGGCTATTC-3′) and oIMR6917 (5′-AGGTGA GATGACAGGAGATC-3′) to yield a product size of 280 bp. Amplification was achieved by PCR (94 °C for 3 min > 35 × 2.5 min cycles (30 s at 94 °C > 60 s at 60 °C > 60 s at 72 °C) > 72 °C for 2 min). The *Bltl* expression was detected by primers oIMR8160 (5′-ATAGCTTTGTAGTGTGGAGCATCCTGA-3′), oIMR8161 (5′-TGGAAGACTTTATGCTCTTTGTTGGGA-3′) and oIMR8162 (5′-TGGATGTGGAATGTGTGCGAG-3′) to yield a product size of 433 bp for WT and 270 bp for mutant. Amplification was achieved by PCR (94 °C for

3 min > 35 × 2.5 min cycles (30 s at 94 °C > 60 s at 64 °C > 60 s at 72 °C) > 72 °C for 2 min). Amplification fragments were visualized on 2% agarose gels.

Mouse infection model. Mice were anaesthetized with isoflurane and infected intranasally (i.n.) with 1 × 10⁶ or 1 × 10⁷ c.f.u. Hib or with 1 × 10⁵ or 1 × 10⁶ c.f.u. *S. pneumoniae* in 50 µl of sterile PBS. Mice were monitored daily and weight loss was recorded. In neutrophil depletion experiments, 129/S6 mice received intraperitoneal (i.p.) administration of 500 µg and i.n. administration of 200 µg of anti-Ly6G (1A8, Bio X Cell, West Lebanon, NH) or control rat IgG (2A3, Bio X Cell) the day preceding and the day of infection and culled 24 h later. In alveolar macrophage-depletion experiments, 129/S6 mice received i.n. administration of 50 µl of control or clodronate liposomes (ClodronateLiposomes.com) 24 and 48 h before infection and culled 24 h post infection. In some experiments, BLT-1-specific antagonist U-75302 (Cayman Chemical Company, Ann Arbor, MI) or BLT2-specific antagonist LY2552833 (Cayman Chemical Company) or vehicle controls were administered at a dose of 100 µg i.p. to 129/S6 mice 1 h before infection and 9 h post infection before being culled at 24 h post infection. In some experiments, mice were each i.p. administered 500 µg of zileuton (Sigma-Aldrich) the day preceding and the day of infection and culled 24 h later. Zileuton was dissolved in a 50% solution of dimethyl sulfoxide (DMSO) (Sigma-Aldrich) in saline, with a final volume of 100 µl. A similar volume of DMSO was given i.p. to control mice in these experiments. In some experiments, mice were administered i.n. 250 µg AcPGP (BACHEM, Bubendorf, Switzerland) or control AcPPG (BACHEM) peptide 2 h post infection and culled at 24 h. To neutralize PGP, mice were administered RTR peptide (Anaspec peptides, Fremont, CA) at a dose of 100 µg i.n. to mice 1 and 9 h post infection before being culled at 24 h. To neutralize elastin fragments, mice were administered BA4 (Sigma-Aldrich) or control antibody at a dose of 50 µg i.n. to mice on a daily basis from time of infection before being culled at day 4.

Cell recovery and isolation. Mice were administered 3 mg pentobarbital and exsanguinated via the femoral artery. Serum was isolated by centrifugation for 8 min at 5,000g and frozen at −80 °C until required. The lungs were then inflated five times with 1.5 ml PBS via an intratracheal cannula and 100 µl from each mouse removed for enumeration of bacterial burden (see below). The remainder was centrifuged and the supernatant stored at −80 °C. The pellet was resuspended at 10⁶ cells per millilitre in R10F (RPMI containing 10% (vol/vol) FCS, penicillin (50 U ml^{−1}), streptomycin (50 µg ml^{−1}) and L-glutamine (2 mM)) and cell viability was assessed using trypan blue exclusion. Lung tissue was disrupted to a single-cell suspension by passage through a 100-µm sieve (BD labware, New Jersey). 100 µl from each mouse was again removed for enumeration of bacterial burden and the remaining cell suspension was centrifuged for 5 min at 800g and red blood cells lysed by resuspending pellets in ACK buffer (0.15 M ammonium chloride, 1 M potassium hydrogen carbonate and 0.01 M EDTA, pH 7.2) for 3 min at room temperature before centrifugation (800g for 5 min) and resuspending in R10F. Cell viability was assessed by trypan blue exclusion and cells resuspended in R10F at 10⁶ cells per millilitre.

Alveolar macrophages were isolated by adherence of BAL fluid to plastic for 1 h in DMEM at 37 °C, 5% CO₂ and shown to be > 97% pure by flow cytometric analysis. To isolate bone marrow neutrophils, the femur and the tibia from both hind legs were removed and freed of soft tissue attachments, and the extreme distal tip of each extremity was cut off. HBSS containing 15 mM EDTA and 30 mM HEPES was forced through the bone with a syringe. After dispersing cell clumps and passage through a 100-µm sieve (BD labware), red blood cells were lysed by resuspending pellets in ACK buffer (for 3 min at room temperature) before centrifugation (800g 5 min) and washing with HBSS. The cell suspension was centrifuged (800g, 5 min, 4 °C) and resuspended in RPMI. The cells were layered onto a 72, 64, 52% Percoll gradient (Sigma-Aldrich) diluted in PBS (100% Percoll = nine parts Percoll and one part 10 × PBS), and centrifuged (1,500g, 30 min, room temperature) without braking. The neutrophils at the 64/72% interface were harvested and washed with 20 ml RPMI. Cell viability was assessed by trypan blue exclusion and confirmed to be > 90% neutrophils by flow cytometry.

Bacterial c.f.u. enumeration. BALF and lung suspension (as detailed above) were serially diluted in sterile PBS and plated onto appropriate agar plates (Columbia blood agar plates for *S. pneumoniae*, BHI agar with 4% Levinthals for Hib) and grown overnight at 37 °C with 5% CO₂. Resultant colonies were counted manually. *S. pneumoniae* was confirmed by optochin sensitivity. Hib was confirmed by no growth on BHI agar without Levinthals.

Flow cytometry. Single-cell suspensions were stained for surface markers in PBS containing 0.1% sodium azide and 1% BSA for 30 min at 4 °C and fixed with 2% paraformaldehyde. Data were acquired on a BD FACS Fortessa machine (BD Biosystems, UK). Forward-scatter and side-scatter gates were used to exclude debris, and dead cells were excluded using a fixable near-infrared dead cell stain kit for 633 or 635 nm excitation. Cell types were characterized by their forward- and side-scatter profiles and by their phenotypes, as depicted in Table 1.

Table 1 | Characterization of immune cells by flow cytometry.

Cell type	Surface marker phenotype	Monoclonal antibody conjugate	Catalogue number	Dilution
B cells	CD19 ⁺	CD19-FITC (BD Biosciences)	557398	1/100
	CD3 [−]	CD3-PECy7 (eBioscience)	25-0031	1/200
Natural killer (NK) cells	NKp46 ⁺	NKp46-PE (eBioscience)	12-3351	1/200
	CD3 [−]	CD3-PECy7 (eBioscience)	25-0031	1/200
CD4 ⁺ T cells	CD4 ⁺	CD4-PerCP (BD Biosciences)	553052	1/200
	CD3 ⁺	CD3-PECy7 (eBioscience)	25-0031	1/200
CD8 ⁺ T cells	CD8 ⁺	CD8-APC (BD Biosciences)	553035	1/200
	CD3 ⁺	CD3-PECy7 (eBioscience)	25-0031	1/200
Neutrophils	Ly-6G ^{high}	Ly6G-FITC (BD Biosciences)	551460	1/100
	CD11b ^{high}	CD11b-PerCP (eBioscience)	45-0112	1/400
	CD11c ^{low}	CD11c-APC (BD Biosciences)	550261	1/200
	F4/80 ^{low}	F4/80-PE (eBioscience)	12-4801	1/50
Alveolar macrophages	CD11b ^{low-int.}	CD11b-PerCP (eBioscience)	45-0112	1/400
	CD11c ^{high}	CD11c-APC (BD Biosciences)	550261	1/200
	F4/80 ^{high}	F4/80-PE (eBioscience)	12-4801	1/50
Inflammatory monocytes/macrophages	CD11b ^{high}	CD11b-PerCP (eBioscience)	45-0112	1/400
	CD11c ^{low}	CD11c-APC (BD Biosciences)	550261	1/200
	F4/80 ^{high}	F4/80-PE (eBioscience)	12-4801	1/50

Treatment of neutrophils with AcPGP. Pre-warmed neutrophil suspensions (37 °C, 2 × 10⁶ cells per millilitre) were incubated in 1% BSA/HBSS with or without AcPGP (0.1 mg ml^{−1}; BACHEM) or IL-8 (1 µg ml^{−1}) for 15 min at 37 °C in 5% CO₂. The level of enzymes released in cell-free supernatant was measured by enzyme-linked immunosorbent (ELISA)-based assays (see below).

Alveolar macrophage and neutrophil phagocytosis assay. Alveolar macrophages (pre-adhered; 1 × 10⁵) or bone-marrow-derived neutrophils (in suspension; 1 × 10⁵) from WT and blt1^{−/−} mice were incubated with *H. influenzae* b (multiplicity of infection 20:1; with 10% serum) conjugated with pHrodo dye utilizing the pHrodo Phagocytosis Particle Labelling Kit (Invitrogen, USA) and phagocytosis assessed by flow cytometry according the manufacturer's directions. pHrodo is a fluorogenic dye that exhibits low fluorescence at neutral pH but fluoresces in acidic environments, allowing accurate measurement of the engulfment of pHrodo-labelled bacteria into the acidic phagosome.

Alveolar macrophage- and neutrophil-killing assay. Alveolar macrophages (pre-adhered; 5 × 10⁵) or bone-marrow-derived neutrophils (in suspension; 1 × 10⁶) from WT and blt1^{−/−} mice were infected with *H. influenzae* b (multiplicity of infection 1:1) in RPMI with 5% serum at 37 °C. After 15 min, extracellular bacteria were removed by washing 3 × with ice-cold RPMI and cells were resuspended in 300 µl RPMI/5% serum and incubated at 37 °C. At 0, 30 and 60 min, 100 µl samples were removed and diluted into 900 µl H₂O. Cells were allowed to lyse by standing at room temperature for 10 min and were subsequently vortexed vigorously to disperse bacteria. Samples were further diluted in H₂O, plated on BHI agar with 4% Levinthals and grown overnight at 37 °C with 5% CO₂. Resultant colonies were counted and % original c.f.u. burden determined relative to the *t* = 0-min time point.

Protease quantification and activity. The concentration of MMP-9 in BALF and neutrophil supernatants was measured using an ELISA, according to the manufacturer's directions (R&D Systems, Minneapolis, MN). To assess MMP-9 gelatinolytic activity, BALF was mixed 1:1 (vol:vol) with Tris-Glycine-SDS Sample Buffer (Life Technologies Ltd, Paisley, UK) and loaded onto 10% zymogram (gelatin) gels (Life Technologies Ltd). Samples were subsequently electrophoresed at 125 V for 90 min in Tris-Glycine-SDS Running Buffer (Life Technologies Ltd). Following electrophoresis, gels were incubated in 1 × Zymogram Renaturing Buffer (Life Technologies Ltd) for 30 min at room temperature. To visualize the gelatinolytic activity, the gel was incubated in 1 × Zymogram Developing Buffer (Life Technologies Ltd) overnight at 37 °C before staining with SimplyBlue Safestain (Life Technologies Ltd).

The concentrations of LTA₄H, NE and MMP-12 in BALF and/or neutrophil supernatants were measured using an ELISA, according to the manufacturer's directions (USCN Life Science, Hubei, PRC).

PE activity assay. Twenty microlitre of BALF was incubated with a specific substrate (2 mM Benzylcarboxy-Glycine-Proline-para-Nitroaniline, ZGP-pNa;

Chem-Impex, Wood Dale, IL) at 37 °C and 5% CO₂ and cleavage of para-nitroaniline (pNa) from the substrate by PE was detected using a spectrophotometer at 410 nm.

ESI-LC/MS/MS for PGP detection. For peptide quantification in BALF, PGP and AcPGP were measured using a MDS Sciex (Applied Biosystems, Foster City, CA) API-4000 spectrometer equipped with a Shimadzu HPLC (Columbia, MD). For peptide quantification from degradation experiments, PGP and AcPGP were measured using a Thermo Accela Pump and Autosampler coupled to a Thermo TSQ Quantum Access. HPLC was done using a 2.0 × 150-mm Jupiter 4u Proteo column (Phenomenex, Torrance, CA) with A: 0.1% HCOOH and B: MeCN + 0.1% HCOOH: 0–0.5 min 5% buffer B/95% buffer A, then increased over 0.5–2.5 min to 100% buffer B/0% buffer A. Background was removed by flushing with 100% isopropanol/0.1% formic acid. Positive electrospray mass transitions were at 270–70, 270–116 and 270–173 for PGP and 312–140 and 312–112 of AcPGP.

PGP degradation experiments. Bronchoalveolar lavage fluid (diluted 1/10 in PBS) was incubated with 0.4 mM PGP at 37 °C and 5% CO₂ for 2 h. Concentrations of PGP remaining were subsequently quantified by electrospray ionization (ESI)–liquid chromatography (LC)/mass spectrometry (MS)/MS (as discussed above) by comparison with PGP standards. The percentage of peptide degraded was determined relative to control samples of 0.4 mM PGP alone.

Measurement of free proline. Aliquots from PGP degradation experiments were diluted 1 in 10 in PBS (to a final volume of 250 µl). Glacial acetic acid (250 µl) was then added, followed by 250 µl of ninhydrin solution (25 mg/ml in acetic acid/6 M phosphoric acid; heated at 70 °C to dissolve). The reaction mixture was heated at 100 °C for 60 min, allowed to cool to room temperature and the proline containing fraction extracted with 500 µl of toluene and optical density measured at 520 nm.

LTA₄H epoxide hydrolase activity. 50 µl of the BAL cell suspension was added to 50 µl of RPMI and treated with A23187 at a final concentration of 2 µg/ml. 1% DMSO was used as a control. Cells were incubated for 20 minutes at 37 °C, and supernatants removed and stored at −80 °C for subsequent LTB₄ analysis (as described below).

LTB₄ quantification. The actual concentration of LTB₄ in the BALF and that generated in the epoxide hydrolase activity assay (above) was assayed using an ELISA, according to manufacturer's directions (R&D systems) or for maximal sensitivity/specificity using a MDS Sciex (Applied Biosystems) API-4000 spectrometer equipped with a Shimadzu HPLC. HPLC was done using a 2.1 × 100 mm Kinetex column (Phenomenex) with A: 10 mM NH₄OAc and B: MeCN + 10 mM NH₄OAc: 0–0.5 min 5% buffer B/95% buffer A, then increased over 0.5–5 min to 100% buffer B/0% buffer A. Negative electrospray mass transitions were at 335–195, 335–151 and 335–123 for LTB₄.

Cytokine/chemokine quantification. The levels of CXCL1/KC, CXCL2/MIP-2, MCP-1/CCL2, C5a, Lungkine/CXCL15, TNF- α , IL-6 (Duo Set; R&D Systems) and MCP-3/CCL7 (MyBiosource, San Diego, CA) were measured according to the manufacturer's instructions.

Albumin ELISA. The concentration of albumin in BALF was measured using an ELISA, according to the manufacturer's directions (Bethyl Laboratories, Montgomery, TX).

Lactate dehydrogenase (LDH) assay. LDH activity in BALF was assessed using the Lactate Dehydrogenase Activity Assay Kit (Sigma-Aldrich). Equal volumes of LDH substrate, LDH assay dye and LDH assay cofactor preparation were combined and 100 μ l was added to 50 μ l of sample. The samples were incubated at room temperature in the dark for 30 min. The reaction was stopped using 30 μ l 1 N HCl and absorbance determined using a spectrophotometer (490 nm).

Real-time PCR. Total RNA was extracted from 50 to 100 mg of lung tissue (azygous lobe) using a Qiagen RNeasy Mini Kit. Total RNA (1 μ g) was reverse transcribed into complementary DNA using a High Capacity cDNA Reverse Transcription Kit (Life Technologies) as per the manufacturer's instructions. Real-time PCR reactions were performed using fast-qPCR mastermix (Life technologies) on a ViiA-7 instrument (Life Technologies) with TaqMan primer sets for murine ENA-78/CXCL5, MCP-1/CCL2, MCP-3/CCL7, MMP-9, MMP-12, GAPDH or HPRT (Life Technologies), and gene expression was analysed using the change-in-threshold $\Delta\Delta C_t$ method; fold changes in mRNA expression for targeted genes were calculated relative to naive WT controls.

Statistical analysis. Statistical significance was calculated using an unpaired Mann–Whitney test. All *P* values of ≤ 0.05 (*) and ≤ 0.01 (**) were considered significant and are referred to as such in the text.

References

- Reeves, E. P. *et al.* Killing activity of neutrophils is mediated through activation of proteases by K + flux. *Nature* **416**, 291–297 (2002).
- Stuart, L. M. & Ezekowitz, R. A. Phagocytosis: elegant complexity. *Immunity* **22**, 539–550 (2005).
- Rot, A. & von Andrian, U. H. Chemokines in innate and adaptive host defense: basic chemokines grammar for immune cells. *Annu. Rev. Immunol.* **22**, 891–928 (2004).
- Nathan, C. Neutrophils and immunity: challenges and opportunities. *Nat. Rev. Immunol.* **6**, 173–182 (2006).
- Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. *Nat. Rev. Immunol.* **11**, 519–531 (2011).
- O'Donnell, R., Breen, D., Wilson, S. & Djukanovic, R. Inflammatory cells in the airways in COPD. *Thorax* **61**, 448–454 (2006).
- Rowe, S. M., Miller, S. & Sorscher, E. J. Cystic fibrosis. *N. Engl. J. Med.* **352**, 1992–2001 (2005).
- Djekic, U. V., Gagg, A. & Weathington, N. M. Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. *Pharmacol. Ther.* **121**, 132–146 (2009).
- Shapiro, S. D. *et al.* Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. *Am. J. Pathol.* **163**, 2329–2335 (2003).
- Churg, A. *et al.* Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. *Am. J. Respir. Cell Mol. Biol.* **27**, 368–374 (2002).
- Houghton, A. M. *et al.* Elastin fragments drive disease progression in a murine model of emphysema. *J. Clin. Invest.* **116**, 753–759 (2006).
- Hautamaki, R. D., Kobayashi, D. K., Senior, R. M. & Shapiro, S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. *Science* **277**, 2002–2004 (1997).
- Weathington, N. M. *et al.* A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. *Nat. Med.* **12**, 317–323 (2006).
- Gagg, A. *et al.* A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. *J. Immunol.* **180**, 5662–5669 (2008).
- Hardison, M. T. *et al.* The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. *J. Immunol.* **182**, 4423–4431 (2009).
- O'Reilly, P. *et al.* N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD. *Respir. Res.* **10**, 38 (2009).
- O'Reilly, P. J. *et al.* Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. *BMJ Open* **3**, e004140 (2013).
- Wells, J. M. *et al.* An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **190**, 51–61 (2014).
- Snelgrove, R. J. *et al.* A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. *Science* **330**, 90–94 (2010).
- Haeggstrom, J. Z., Tholander, F. & Wetterholm, A. Structure and catalytic mechanisms of leukotriene A4 hydrolase. *Prostaglandins Other Lipid Mediat.* **83**, 198–202 (2007).
- Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* **294**, 1871–1875 (2001).
- Tager, A. M. & Luster, A. D. BLT1 and BLT2: the leukotriene B(4) receptors. *Prostaglandins Leukot. Essent. Fatty Acids* **69**, 123–134 (2003).
- Di Gennaro, A. & Haeggstrom, J. Z. The leukotrienes: immune-modulating lipid mediators of disease. *Adv. Immunol.* **116**, 51–92 (2012).
- Whittle, B. J. *et al.* Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. *Br. J. Pharmacol.* **153**, 983–991 (2008).
- Griffiths, R. J. *et al.* Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. *Proc. Natl Acad. Sci. USA* **92**, 517–521 (1995).
- Baile, M. B. *et al.* Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. *J. Immunol.* **157**, 5221–5224 (1996).
- Chen, X. S., Sheller, J. R., Johnson, E. N. & Funk, C. D. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. *Nature* **372**, 179–182 (1994).
- Snelgrove, R. J. Leukotriene A4 hydrolase: an anti-inflammatory role for a proinflammatory enzyme. *Thorax* **66**, 550–551 (2011).
- Fourie, A. M. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. *Curr. Opin. Investig. Drugs* **10**, 1173–1182 (2009).
- Barchuk, W. *et al.* Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma. *Pulm. Pharmacol. Ther.* **29**, 15–23 (2014).
- Ulanova, M. & Tsang, R. S. Invasive Haemophilus influenzae disease: changing epidemiology and host-parasite interactions in the 21st century. *Infect. Genet. Evol.* **9**, 594–605 (2009).
- Ulanova, M. & Tsang, R. S. Haemophilus influenzae serotype a as a cause of serious invasive infections. *Lancet Infect. Dis.* **14**, 70–82 (2014).
- Kelly, D. F., Moxon, E. R. & Pollard, A. J. Haemophilus influenzae type b conjugate vaccines. *Immunology* **113**, 163–174 (2004).
- O'Reilly, P. J. *et al.* Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen. *J. Neuroimmunol.* **217**, 51–54 (2009).
- Overbeek, S. A. *et al.* Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? *PLoS ONE* **8**, e55612 (2013).
- Braber, S. *et al.* Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **300**, L255–L265 (2010).
- Serezani, C. H., Aronoff, D. M., Jancar, S., Mancuso, P. & Peters-Golden, M. Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase. *Blood* **106**, 1067–1075 (2005).
- Soares, E. M. *et al.* Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent Streptococcus pyogenes. *J. Immunol.* **190**, 1614–1622 (2013).
- Mancuso, P., Nana-Sinkam, P. & Peters-Golden, M. Leukotriene B4 augments neutrophil phagocytosis of Klebsiella pneumoniae. *Infect. Immun.* **69**, 2011–2016 (2001).
- Mancuso, P., Lewis, C., Serezani, C. H., Goel, D. & Peters-Golden, M. Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia. *Infect. Immun.* **78**, 2264–2271 (2010).
- Serezani, C. H., Perrella, J. H., Russo, M., Peters-Golden, M. & Jancar, S. Leukotrienes are essential for the control of Leishmania amazonensis infection and contribute to strain variation in susceptibility. *J. Immunol.* **177**, 3201–3208 (2006).
- Peres, C. M. *et al.* Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. *Microbes Infect.* **9**, 483–489 (2007).
- Wirth, J. J. & Kierszenbaum, F. Stimulatory effects of leukotriene B4 on macrophage association with and intracellular destruction of Trypanosoma cruzi. *J. Immunol.* **134**, 1989–1993 (1985).
- Mancuso, P., Standiford, T. J., Marshall, T. & Peters-Golden, M. 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of Klebsiella pneumoniae. *Infect. Immun.* **66**, 5140–5146 (1998).
- Mancuso, P. & Peters-Golden, M. Modulation of alveolar macrophage phagocytosis by leukotrienes is Fc receptor-mediated and protein kinase C-dependent. *Am. J. Respir. Cell Mol. Biol.* **23**, 727–733 (2000).
- Demitsu, T., Katayama, H., Saito-Taki, T., Yaoita, H. & Nakano, M. Phagocytosis and bactericidal action of mouse peritoneal macrophages treated with leukotriene B4. *Int. J. Immunopharmacol.* **11**, 801–808 (1989).

47. Talvani, A. *et al.* Leukotriene B(4) induces nitric oxide synthesis in Trypanosoma cruzi-infected murine macrophages and mediates resistance to infection. *Infect. Immun.* **70**, 4247–4253 (2002).
48. Coffey, M. J., Phare, S. M. & Peters-Golden, M. Role of leukotrienes in killing of Mycobacterium bovis by neutrophils. *Prostaglandins Leukot. Essent. Fatty Acids* **71**, 185–190 (2004).
49. Larfars, G., Lanttoine, F., Devynck, M. A., Palmblad, J. & Gyllenhammar, H. Activation of nitric oxide release and oxidative metabolism by leukotrienes B₄, C₄, and D₄ in human polymorphonuclear leukocytes. *Blood* **93**, 1399–1405 (1999).
50. Ito, N. *et al.* Requirement of phosphatidylinositol 3-kinase activation and calcium influx for leukotriene B₄-induced enzyme release. *J. Biol. Chem.* **277**, 44898–44904 (2002).
51. van Houwelingen, A. H. *et al.* Induction of lung emphysema is prevented by L-arginine-threonine-arginine. *FASEB J.* **22**, 3403–3408 (2008).
52. Pfister, R. R. *et al.* Synthetic complementary peptides inhibit a neutrophil chemoattractant found in the alkali-injured cornea. *Cornea* **19**, 384–389 (2000).
53. Rao, N. L. *et al.* Anti-inflammatory activity of a potent, selective leukotriene A₄ hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. *J. Pharmacol. Exp. Ther.* **321**, 1154–1160 (2007).
54. He, J., Turino, G. M. & Lin, Y. Y. Characterization of peptide fragments from lung elastin degradation in chronic obstructive pulmonary disease. *Exp. Lung Res.* **36**, 548–557 (2013).
55. Blanchevoys, C. *et al.* Interaction between the elastin peptide VGVAPG and human elastin binding protein. *J. Biol. Chem.* **288**, 1317–1328 (2013).
56. Haeggstrom, J. Z. Structure, function, and regulation of leukotriene A₄ hydrolase. *Am. J. Respir. Crit. Care Med.* **161**, S25–S31 (2000).
57. Goulet, J. L., Snouwaert, J. N., Latour, A. M., Coffman, T. M. & Koller, B. H. Altered inflammatory responses in leukotriene-deficient mice. *Proc. Natl Acad. Sci. USA* **91**, 12852–12856 (1994).
58. Kim, S. D. *et al.* Activation of CXCR2 by extracellular matrix degradation product acetylated-Pro-Gly-Pro has therapeutic effects against sepsis. *Am. J. Respir. Crit. Care Med.* **184**, 243–251 (2011).
59. Xu, X. *et al.* A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. *PLoS ONE* **6**, e15781 (2011).
60. Senior, R. M., Griffin, G. L. & Mecham, R. P. Chemotactic activity of elastin-derived peptides. *J. Clin. Invest.* **66**, 859–862 (1980).
61. Senior, R. M. *et al.* Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. *J. Cell Biol.* **99**, 870–874 (1984).
62. Hunninghake, G. W. *et al.* Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. *Science* **212**, 925–927 (1981).
63. Byrum, R. S., Goulet, J. L., Snouwaert, J. N., Griffiths, R. J. & Koller, B. H. Determination of the contribution of cysteinyl leukotrienes and leukotriene B₄ in acute inflammatory responses using 5-lipoxygenase- and leukotriene A₄ hydrolase-deficient mice. *J. Immunol.* **163**, 6810–6819 (1999).
64. Shim, Y. M. *et al.* Role of LTB₄ in the pathogenesis of elastase-induced murine pulmonary emphysema. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **299**, L749–L759 (2010).
65. Hardison, M. T., Brown, M. D., Snelgrove, R. J., Blalock, J. E. & Jackson, P. Cigarette smoke enhances chemotaxis via acetylation of proline-glycine-proline. *Front. Biosci. (Elite Ed.)* **4**, 2402–2409 (2012).
66. Wedzicha, J. A., Brill, S. E., Allinson, J. P. & Donaldson, G. C. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. *BMC Med.* **11**, 181 (2013).
67. Mercer, P. F. *et al.* MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. *Respir. Res.* **6**, 151 (2005).
68. Snelgrove, R. J. Targeting of a common receptor shared by CXCL8 and N-Ac-PGP as a therapeutic strategy to alleviate chronic neutrophilic lung diseases. *Eur. J. Pharmacol.* **667**, 1–5 (2011).
69. De Oliveira, E. O. *et al.* Effect of the leukotriene A₄ hydrolase aminopeptidase augmentor 4-methoxydiphenylmethane in a pre-clinical model of pulmonary emphysema. *Bioorg. Med. Chem. Lett.* **21**, 6746–6750 (2011).
70. Paige, M. *et al.* Role of leukotriene A₄ Hydrolase aminopeptidase in the pathogenesis of emphysema. *J. Immunol.* **192**, 5059–5068 (2014).

Acknowledgements

R.J.S. is a Wellcome Trust Career Development Fellow (095707/Z/11/Z). C.M.L. is a Wellcome Trust Senior Fellow in Basic Biomedical Sciences (087618/Z/08/Z). T.P. is supported by a Marie Curie Intra European Fellowship within the 7th European Community Framework Programme (FP7-PEOPLE-2013-IEF No. 627374). The National Heart, Lung and Blood Institute funds J.E.B. (HL07783, HL110950 and HL114439) and A.G. (HL102371-A1). The UAB Lung Health Center Pulmonary Proteomics Laboratory is funded through the NIH (RR19231, P30CA13148, P50AT00277, U54CA100949, P30AR050948 and P30DK740380). We would like to thank Dr Anna Caldwell and the Centre of Excellence for Mass Spectrometry at King's College London for the use of equipment and technical assistance.

Author contributions

R.J.S. planned, executed and interpreted the experiments and prepared the manuscript. S.A. performed many experiments and assisted with the analysis. R.C.B., D.F.P., T.P. and X.X. provided technical contributions to the paper. P.L.J. aided with mass spectrometry. A.G., P.L.J., J.E.B. and C.M.L. contributed discussions throughout the work.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Akthar, S. *et al.* Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection. *Nat. Commun.* **6**:8423 doi: 10.1038/ncomms9423 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>